Company: SNY
Filing Date: 2025-10-29
Form Type: 424B5
Source: 0001193125-25-255563
Chunk: 30

Company: Sanofi
Filing Date: 2025-10-29
Form: 424B5
Chunk 30
---
8,202 |
| (C) Long-term debt                                            |     |                       | 11,700 |     |                 | 14,277 |
| (D) Equity attributable to non-controlling                    
 interests                                                     |     |                       |    270 |     |                 |    270 |
| (E) Equity attributable to equity holders of Sanofi           |     |                       | 73,263 |     |                 | 73,263 |
| (F) Capitalization (C+D+E)                                    |     |                       | 85,233 |     |                 | 87,810 |

| (1) | For the purposes of the amounts shown in this table, the aggregate principal amount of the notes issued                                                                                                                           
 pursuant to this prospectus supplement has been converted from U.S. dollars to euro using an exchange rate of €1.00 = U.S.$1.164, the European Central Bank rate on October 27, 2025, for a total amount of €2,577 million which, 
 after deducting underwriting discounts and commissions and estimated offering expenses, amounts to €2,565 million.                                                                                                                |

| (2) | None of the amounts in this table reflect significant transactions that have occurred since September 30, 
 2025.                                                                                                     |

| (3) | Since September 30, 2025, Sanofi has issued U.S. commercial paper for a total amount of $1.0 billion                                                   
 and has repaid $2.1 billion of the issued U.S. commercial paper, resulting in a net decrease of $1.1 billion of Sanofi’s outstanding commercial paper. |

S-21

USE OF PROCEEDS

The net proceeds of the offering, after deduction of underwriting discounts and commissions and expenses, amount to approximately
$2,986,198,000.

We intend to use the net proceeds for general corporate purposes.

S-22

DESCRIPTION OF THE NOTES

The following description of the particular terms of the notes supplements and, as applicable, supersedes the description of the general terms set forth in the attached prospectus under the heading “Description of Debt Securities We May Offer.” It is important for you to consider the information contained in this prospectus supplement and the attached prospectus before making your decision to invest in the notes. If any specific information regarding the notes in this prospectus supplement is inconsistent with the more general terms of the notes described in the attached prospectus, you should rely on the information contained